PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
VALBY, Denmark , June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) ...
2026-06-24T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Ping An Good Doctor CEO He Mingke Speaks At 2026 Summer Davos: China Is Entering Its Own "Longevity Era"
HONG KONG and SHANGHAI , June 24, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or the "Group"; HKEX: 2318/82318; SSE: 601318) attended the World ...
2026-06-24T    Banking/Financial Service   Health Care/Hospital   Insurance 
Yidu Tech's Gong Yingying at Summer Davos: Building Evidence Infrastructure to Expand Access to Innovative Medicines
DALIAN, China , June 24, 2026 /PRNewswire/ -- On June 23, at the 17th Annual Meeting of the New Champions (Summer Davos 2026) hosted by the World Economic Forum in Dalian, Gong Yingying, Founder ...
2026-06-24T    Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals   Trade show news 
World's First Solid Tumor CAR-T Approved: Jiahui International Cancer Center Provides Access for Patients Worldwide
SHANGHAI , June 24, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) welcomes the approval of Satri-cel (CT041, Kaileimei®), the world's first CAR-T cell therapy approved for the treatment ...
2026-06-24T    Health Care/Hospital   Medical/Pharmaceuticals 
Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational ...
2026-06-24T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules
SHANGHAI , June 24, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, ...
2026-06-24T    Health Care/Hospital   Medical/Pharmaceuticals 
DuPont Launches Tyvek® APX™ in ASEAN Market
Enhanced breathability without compromising protection or durability helps improve wearer comfort in demanding work environments ...
2026-06-24T    Chemical   Computer/Electronics   Health Care/Hospital   Textiles 
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
SHANGHAI , June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility ...
2026-06-24T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Milliken Expands Innovation Capabilities with New Polymer Solutions Pilot Plant in Pune, India
Facility strengthens ability to accelerate development and scale advanced material solutions for global markets.   ...
2026-06-24T    Chemical   Health Care/Hospital   Machinery   Medical/Pharmaceuticals 
UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapy
SHANGHAI , June 23, 2026 /PRNewswire/ -- UniXell Biotechnology Co., Ltd. ("UniXell") has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for ...
2026-06-24T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.